Logo

Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China

Share this

Samsung Biologics Collaborates with APRINOIA Therapeutics to Expand its Presence in Greater China

Shots:

  • Samsung Biologics entered into an agreement with APRINOIA Therapeutics to develop an anti-tau mAb for treating primary and secondary tauopathies- including PSP and AD
  • APRINOIA will utilize its Ab platform for selecting the candidate and targets specific pathological tau aggregates with novel conformation-dependent epitopes with an aim to slow down disease progression
  • The collaboration encompasses product's development phase from cell line development- process development- cGMP manufacturing to IND filing while with the collaboration Samsung Biologics has reconfirmed its position as a global leading CMO- CDO- and CRO partner

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Samsung Biologics


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions